Profile data is unavailable for this security.
About the company
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
- Revenue in USD (TTM)116.94k
- Net income in USD-8.06m
- Incorporated2019
- Employees10.00
- LocationAltamira Therapeutics LtdClarendon House, 2 Church StreetHAMILTON 6300BermudaBMU
- Phone+41 612011350
- Websitehttps://aurismedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revelation Biosciences Inc | 0.00 | -8.96m | 3.15m | 9.00 | -- | 0.3327 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 3.19m | 9.00 | -- | 0.4186 | -- | 0.2595 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
Aditxt Inc | 506.45k | -41.45m | 3.20m | 47.00 | -- | 0.322 | -- | 6.31 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
Avenue Therapeutics Inc | 0.00 | -7.18m | 3.24m | 3.00 | -- | 0.7159 | -- | -- | -39.36 | -39.36 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -123.08 | -186.91 | -1,045.52 | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
Optimus Healthcare Services Inc | 1.27m | -7.79m | 3.32m | 17.00 | -- | -- | -- | 2.62 | -0.1948 | -0.1948 | 0.0317 | -0.1291 | 0.2595 | -- | 2.16 | 74,453.53 | -159.79 | -- | -2,228.37 | -- | 77.90 | -- | -615.77 | -- | 0.1525 | -15.41 | 21.18 | -- | -- | -- | -- | -- | -- | -- |
Livewire Ergogenics Inc | 67.98k | -1.09m | 3.35m | 1.00 | -- | -- | -- | 49.25 | -0.0061 | -0.0061 | 0.0003 | -0.0022 | 0.1979 | 1.74 | 2.86 | 67,980.00 | -317.45 | -- | -- | -- | -113.70 | -- | -1,604.38 | -- | 0.1248 | -2.13 | -- | -- | 68.58 | -- | -3.64 | -- | -- | -- |
Manuka Inc | 671.00k | -1.14m | 3.36m | 4.00 | -- | -- | -- | 5.01 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
Gold River Productions Inc. | -100.00bn | -100.00bn | 3.37m | 1.00k | -- | 5.19 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 3.41m | 25.00 | -- | -- | -- | 0.2159 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
Bio Path Holdings Inc | 0.00 | -13.96m | 3.41m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
Altamira Therapeutics Ltd | 116.94k | -8.06m | 3.43m | 10.00 | -- | 0.3157 | -- | 29.31 | -31.28 | -26.40 | 0.238 | 4.85 | 0.0151 | 34.05 | 32.30 | 11,694.20 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -6,892.99 | -- | 1.38 | -4.36 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
TRACON Pharmaceuticals Inc | 12.15m | 1.75m | 3.43m | 17.00 | 1.97 | -- | 1.95 | 0.2824 | 0.6509 | 0.6509 | 6.27 | -0.6618 | 1.37 | -- | -- | 714,411.80 | 19.78 | -79.42 | -- | -177.85 | -- | -- | 14.39 | -813.81 | -- | -0.4613 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
60 Degrees Pharmaceuticals Inc | 378.20k | -1.07m | 3.55m | 2.00 | -- | -- | -- | 9.37 | -0.1563 | -0.1563 | 0.0564 | 0.6121 | 0.0474 | 0.8827 | 1.90 | 126,066.70 | -9.87 | -- | -- | -- | -23.45 | -- | -208.43 | -- | 6.77 | -- | 0.0217 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
Clearmind Medicine Inc | 0.00 | -8.09m | 3.58m | -- | -- | 0.7104 | -- | -- | -30.92 | -30.92 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -109.55 | -218.20 | -180.61 | -488.96 | -- | -- | -- | -- | -- | -2.90 | 0.0184 | -- | -- | -- | -25.03 | -- | -- | -- |
Atreca Inc | 0.00 | -97.76m | 3.65m | 90.00 | -- | 0.3391 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
Holder | Shares | % Held |
---|---|---|
Tower Research Capital LLCas of 31 Mar 2024 | 1.66k | 0.07% |
Group One Trading LPas of 31 Mar 2024 | 14.00 | 0.00% |
LRI Investments LLCas of 31 Mar 2024 | 1.00 | 0.00% |
Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 0.00 | 0.00% |
UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |